In a significant scientific achievement, physicians and scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have successfully employed preimplantation genetic diagnosis for retinoblastoma, resulting in the world's first babies born free of the deadly eye cancer. The news appears in this month's issue of the American Journal of Ophthalmology.
After a two-year search, Peter M. Siegel has been named director of Cornell University Network and Computing Systems. Siegel, who has been executive director and director of corporate partnership for Cornell's Center for Theory and Simulation in Science and Engineering.
Ronald J. Herring, a Cornell professor of government and chair of that department since 1993, has been named director of the university’s Mario Einaudi Center for International Studies by Provost Don Randel.
Ph.D. marshal Haley Oliver earns her doctorate, despite overwhelming family crises this past year: her single-parent father was killed, and she had to oversee selling the family farm. (May 22, 2009)
Maurie Semel, Cornell University professor emeritus of entomology, whose research work bolstered the Long Island, N.Y. potato and vegetable industries, died Feb. 10, 2005, in Bucyrus, Ohio. He was 82.
Model minority is a 'myth of the American dream,' says a panelist at the April 20 'Deconstructing the Model Minority' discussion, sponsored by the Asian Political Action Committee, a Cornell student group. (April 25, 2007)
To kick off the new Applied Economics and Management Current Event series, a group of alumni, all financial experts, discussed the mortgage and financial crisis, Sept. 25. (Sept. 30, 2008)
Stephen Paletta '87, winner of the reality TV show 'Oprah's Big Give' in April 2008, is helping to organize a service-learning trip to Rwanda for eight Cornell students starting June 4. (May 19, 2009)
New York, NY (December 2, 2002) -- A widely available dietary supplement, coenzyme Q10, has shown promising results in a clinical trial involving 80 patients with early Parkinson's disease, according to a recent article in the "Archives of Neurology." In the trial--a multicenter, randomized, placebo-controlled, double-blind, and dosage-ranging trial--coenzyme Q10 was shown to be safe, well-tolerated, and significantly effective in slowing the progression of the neurological disorder. And it was clearly dose-dependent - that is, the larger the dose, the greater its effect."Our results are so encouraging that we have to emphasize that they still have to be confirmed by a Phase III clinical trial with a larger group of patients," said Dr. Flint Beal, Chairman of the Department of Neurology and Neuroscience at Weill Cornell Medical College and one of the authors of the article. He and his colleagues caution that the findings may not extend to patients with later stages of Parkinson's or to patients who are at risk but have not been diagnosed with the disorder. Furthermore, if too many people now buy coenzyme Q10 on their own, there may not be enough subjects for a rigorous Phase III trial.